Table 1.
Demographics of the study participants who had hepatic resection during the FOXFIRE clinical trial.
| Characteristic at Baseline 1 | OxMdG | OxMdG + SIRT | Total | |
|---|---|---|---|---|
| (n = 33) | (n = 38) | (n = 71) | ||
| Age at randomisation (years) | 62 (42–78) | 61 (30–83) | 61 (30–83) | |
| Extra-hepatic metastases status | No | 28 (85%) | 31 (82%) | 59 (83%) |
| Yes | 5 (15%) | 7 (18%) | 12 (17%) | |
| Degree of liver involvement | ≤25% | 27 (82%) | 29 (76%) | 56 (79%) |
| >25% | 6 (18%) | 9 (24%) | 15 (21%) | |
| Gender | Male | 22 (67%) | 25 (66%) | 47 (66%) |
| Female | 11 (33%) | 13 (34%) | 24 (34%) | |
| Ethnicity | White or Caucasian | 32 (97%) | 33 (89%) | 65 (93%) |
| Asian | 0 (0%) | 2 (5%) | 2 (3%) | |
| Black or African American | 0 (0%) | 1 (3%) | 1 (1%) | |
| Other | 1 (3%) | 1 (3%) | 2 (3%) | |
| BMI (kg/m2) | ≤30 | 23 (70%) | 33 (87%) | 56 (79%) |
| >30 | 10 (30%) | 5 (13%) | 15 (21%) | |
| WHO performance status | 0 | 29 (88%) | 24 (65%) | 53 (76%) |
| 1 | 4 (12%) | 13 (35%) | 17 (24%) | |
| Metastases present at initial diagnosis | No-Metachronous | 8 (24%) | 5 (14%) | 13 (19%) |
| Yes-Synchronous | 25 (76%) | 32 (86%) | 57 (81%) | |
| Primary tumour site | Left-sided primary | 25 (86%) | 31 (82%) | 56 (84%) |
| Right-sided primary | 4 (14%) | 7 (18%) | 11 (16%) | |
| Primary tumour in situ | No | 14 (42%) | 16 (42%) | 30 (42%) |
| Yes | 19 (58%) | 22 (58%) | 41 (58%) | |
| KRAS | Unknown | 12 (36%) | 10 (26%) | 22 (31%) |
| Wild Type | 15 (45%) | 23 (61%) | 38 (54%) | |
| Mutation | 6 (18%) | 5 (13%) | 11 (15%) | |
| Prior adjuvant chemotherapy | No | 31 (94%) | 37 (97%) | 68 (96%) |
| Yes | 2 (6%) | 1 (3%) | 3 (4%) | |
| Prior pelvic radiotherapy | No | 32 (97%) | 36 (95%) | 68 (96%) |
| Yes | 1 (3%) | 2 (5%) | 3 (4%) | |
1n (%) for categorical variables; median (min–max) for continuous variables. OxMdG: Oxaliplatin, 5-fluorouracil and folic acid; BMI: body mass index; WHO: World Health Organisation performance status; KRAS: Kirsten-RAS gene status.